BioCentury | Jun 15, 2015

LDL in context

Discussion at last week's advisory committee meeting for the PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab suggest that, for first-in-class hypercholesterolemia candidates, the agency and the committee are leaning toward narrowing the use of LDL...
BC Week In Review | Jan 5, 2015
Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
BC Week In Review | Jun 16, 2014
Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
BC Week In Review | Apr 21, 2014
Clinical News

AEM-28: Phase Ia started

LipimetiX Development LLC began a double-blind, placebo-controlled, Australian Phase Ia trial to evaluate single and multiple ascending-doses of IV AEM-28 in about 36 healthy volunteers with elevated cholesterol. LipimetiX Development is a JV between Capstone...
BioCentury | Sep 16, 2013

Benu's virtual play

Benu's virtual play New investment firm Benu BioVentures has the backing of a single investor to establish virtual companies that will develop preclinical programs and move them to Phase II proof of concept using an...
BC Week In Review | Aug 13, 2012
Company News

Capstone Therapeutics, LipimetiX deal

Capstone and LipimetiX formed a 60/40 JV, LipimetiX Development LLC, to develop LipimetiX's mimetics of apolipoprotein E (APOE) . LipimetiX has rights to the compounds from University of Alabama at Birmingham . Capstone will contribute $6 million...
BioCentury | Jun 7, 2010
Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E , a protein that can target two additional hepatic receptors capable of clearing...
BC Week In Review | May 10, 2010
Company News

Benu Biopharma Inc., Exponential Pharma Ventures LLC deal

Benu Biopharma and Exponential Pharma Ventures formed a new virtual company called LipimetiX LLC to develop apolipoprotein E (APOE) mimetics. The newco's lead compounds, AEM-18 and AEM-28 , are in preclinical development to treat refractory hyperlipidemia...
Items per page:
1 - 8 of 8